Venetolax with Azacitidine Drains Fuel from AML Stem Cells

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
• Elderly patients often face limited treatment options and poorer prognoses.
• Novel therapeutic strategies are needed to improve outcomes in newly diagnosed elderly AML.

Purpose of the Study:

• To evaluate the efficacy of a venetoclax and azacitidine combination in newly diagnosed elderly AML patients.
• To investigate the molecular mechanisms underlying the treatment response.

Main Methods:

• A clinical trial was conducted involving newly diagnosed elderly AML patients.
• Patients received a combination of venetoclax and azacitidine.
• Mechanistic studies assessed the impact on cellular metabolism.

Main Results:

• The combination therapy demonstrated a remarkable overall response rate.
• Treatment led to reduced succinate dehydrogenase glutathionylation.
• The therapy impaired the tricarboxylic acid cycle and depleted ATP in leukemia stem cells.

Conclusions:

• Venetoclax and azacitidine represent a promising treatment for elderly AML.
• The combination effectively targets leukemia stem cells by disrupting their energy production.
• Further research is warranted to optimize this regimen.